Allogeneic hematopoietic stem cell transplantation for myelofibrosis

Current Opinion in Hematology

Volumn 13, Issue 2, 2006, Pages 74-78

  Barosi, Giovanni ^a   Bacigalupo, Andrea ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

Allogeneic hemopoietic stem cell transplantation; Graft versus host disease; Myelofibrosis with myeloid metaplasia; Reduced intensity conditioning

Indexed keywords

BUSULFAN; FLUDARABINE; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CLINICAL TRIAL; CONDITIONING REGIMEN; DRUG DOSE REDUCTION; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE DEPLETION; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK CLASSIFICATION; SPLENECTOMY; T LYMPHOCYTE; TUMOR VOLUME;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELOFIBROSIS; MYELOID METAPLASIA; PRIMARY MYELOFIBROSIS; SPLENECTOMY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646807170     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000203191.99447.98     Document Type: Review

References (21)

1. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93:2831-2838.
2. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102:3912-3918.
3. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003; 32:35-40.
4. Ditschkowski M, Beelen DW, Trenschel R, et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004; 34:807-813.
5. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004; 33:1005-1009.
6. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004; 33:691-696. This is the report of the Third Zurich EBMT/AMGEN Workshop on RIC-HSCT, convened early in 2003, in which a total of 1846 RIC transplants were presented. The incidence of acute GvHD grade III-IV was 11%, extensive chronic GvHD 22%. TRM (1 year) was 20%, survival 60% and relapse 31%.
7. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99:2255-2258.
8. Hessling J, Kroger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119:769-772.
9. Hertenstein B, Guardiola P, Finke J, et al. Non-myeloablative (NMA) stem cell transplantation (SCT) for myeloid metaplasia with myelofibrosis (MMM): a survey from the Chronic Leukemia Working Party of the EBMT [abstract]. Blood 2002; 100:70a.
10. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105:4115-4119. First paper reporting extensive analysis of 21 patients with MMM receiving RIC allogeneic HSCT.
11. Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia [letter]. N Engl J Med 2000; 343:659-660.
12. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128:690-697. Report of 21 patients with MMM confirming that RIC regimens associated with ATG/ALG treatment produce low TRM and high rate of survival.
13. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013-1018.
14. Kalhas P, Schwartzinger I, Anderson G, et al. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host- disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukaemia. Blood 1995; 86:2028-2032.
15. Michallet M, Corront B, Bosson JL, et al. Role of splenectomy in incidence and severity of acute graft-versus-host-disease: a multicenter study of 157 patients. Bone Marrow Transplant 1991; 8:13-17.
16. Li Z, Gooley T, Appelbaum FR, Deeg HJ. Splenectomy and hematopoietic stem cell transplantation for myelofibrosis. Blood 2001; 97:2180-2181.
17. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7:200-206.
18. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95:2226-2233.
19. Li Z, Deeg HJ. Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation. Leukemia 2001; 15:465-467.
20. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102:684-690.
21. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104:579-585. A Markov model to examine three transplantation strategies for newly diagnosed MDS patients: transplantation at diagnosis, transplantation at leukemic progression, and transplantation at an interval from the diagnosis but prior to leukemic progression. The results, which can be usefully translated to MMM patients, documented that for low and intermediate-1-risk MDS, delayed HSCT is associated with maximal life expectancy.